CL2022000262A1 - Métodos de identificación de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa (divisional de la solicitud no. 202100251) - Google Patents

Métodos de identificación de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa (divisional de la solicitud no. 202100251)

Info

Publication number
CL2022000262A1
CL2022000262A1 CL2022000262A CL2022000262A CL2022000262A1 CL 2022000262 A1 CL2022000262 A1 CL 2022000262A1 CL 2022000262 A CL2022000262 A CL 2022000262A CL 2022000262 A CL2022000262 A CL 2022000262A CL 2022000262 A1 CL2022000262 A1 CL 2022000262A1
Authority
CL
Chile
Prior art keywords
benefit
treatment
telomerase inhibitor
methods
identifying patients
Prior art date
Application number
CL2022000262A
Other languages
English (en)
Inventor
Fei Huang
Jacqueline Cirillo Bussolari
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of CL2022000262A1 publication Critical patent/CL2022000262A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Signal Processing (AREA)
  • Dermatology (AREA)

Abstract

Esta descripción proporciona métodos para identificar o seleccionar un paciente con posibilidades de beneficiarse de un tratamiento con un inhibidor de la telomerasa, como por ejemplo imetelstat, realizando una prueba a un paciente para determinar: la ausencia de una mutación en cada uno de JAK2, CALR y MPL; y/o un alto riesgo molecular (HMR), basado en la presencia de una mutación en al menos uno de los siguientes genes: ASXL1, EZH2, SRSF2 e IDH1/2. El paciente puede padecer mielofibrosis. La descripción también proporciona métodos para tratar la mielofibrosis, que incluyen la identificación de dichos pacientes.
CL2022000262A 2018-07-31 2022-02-01 Métodos de identificación de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa (divisional de la solicitud no. 202100251) CL2022000262A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862712841P 2018-07-31 2018-07-31
US201862772849P 2018-11-29 2018-11-29

Publications (1)

Publication Number Publication Date
CL2022000262A1 true CL2022000262A1 (es) 2022-10-21

Family

ID=69230556

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2021000251A CL2021000251A1 (es) 2018-07-31 2021-01-29 Métodos de identificación de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa
CL2022000262A CL2022000262A1 (es) 2018-07-31 2022-02-01 Métodos de identificación de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa (divisional de la solicitud no. 202100251)
CL2023003123A CL2023003123A1 (es) 2018-07-31 2023-10-19 Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa
CL2023003126A CL2023003126A1 (es) 2018-07-31 2023-10-19 Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2021000251A CL2021000251A1 (es) 2018-07-31 2021-01-29 Métodos de identificación de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2023003123A CL2023003123A1 (es) 2018-07-31 2023-10-19 Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa
CL2023003126A CL2023003126A1 (es) 2018-07-31 2023-10-19 Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa

Country Status (15)

Country Link
US (1) US20200063214A1 (es)
EP (1) EP3829651A4 (es)
JP (2) JP7401518B2 (es)
KR (1) KR20210038895A (es)
CN (1) CN112770783A (es)
AU (1) AU2019315406A1 (es)
BR (1) BR112021001204A2 (es)
CA (1) CA3104537A1 (es)
CL (4) CL2021000251A1 (es)
IL (1) IL279623A (es)
MA (1) MA53348A (es)
MX (1) MX2021001255A (es)
SG (1) SG11202012682PA (es)
TW (1) TW202021626A (es)
WO (1) WO2020028261A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2717777T3 (es) 2013-11-06 2019-06-25 Mayo Found Medical Education & Res Métodos y materiales para tratar neoplasias hematológicas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200327B2 (en) * 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
WO2014085632A1 (en) * 2012-11-30 2014-06-05 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
ES2717777T3 (es) * 2013-11-06 2019-06-25 Mayo Found Medical Education & Res Métodos y materiales para tratar neoplasias hematológicas
AU2016248317A1 (en) * 2015-04-15 2017-11-09 Promedior, Inc. Methods for treating myeloproliferative disorders

Also Published As

Publication number Publication date
JP2021531793A (ja) 2021-11-25
CL2023003123A1 (es) 2024-04-19
CL2021000251A1 (es) 2021-08-20
IL279623A (en) 2021-03-01
AU2019315406A1 (en) 2021-01-21
MA53348A (fr) 2022-05-04
BR112021001204A2 (pt) 2021-04-27
EP3829651A1 (en) 2021-06-09
US20200063214A1 (en) 2020-02-27
CL2023003126A1 (es) 2024-04-19
CN112770783A (zh) 2021-05-07
EP3829651A4 (en) 2022-05-04
JP7401518B2 (ja) 2023-12-19
CA3104537A1 (en) 2020-02-06
JP2023164560A (ja) 2023-11-10
TW202021626A (zh) 2020-06-16
KR20210038895A (ko) 2021-04-08
SG11202012682PA (en) 2021-02-25
MX2021001255A (es) 2021-04-12
WO2020028261A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
NI201700035A (es) Uso de paneles de genes mutantes del fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor del fgfr
Ibrayeva et al. Early stem cell aging in the mature brain
CO6331372A2 (es) Inhibidor de parp 4-yodo-3-nitrobenzamida o un metabolito de la misma
CL2023003126A1 (es) Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa
AR084831A1 (es) Terapia anticancer mediante inhibidores de quinasa
ECSP088171A (es) Metodo para la prediccion de la respuesta a un tratamiento
CL2020002103A1 (es) Anticuerpos anti-htra1 y metodos de uso de los mismos. (divisional solicitud 201801139)
NI201200128A (es) Identificación de mutación de lkb1 como un biomarcador predictivo de sensibilidad a los inhibidores de cinasa de tor.
CL2022001256A1 (es) Métodos y composiciones para tratar un trastorno asociado con el angiotensinogeno agt
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
BR112015012507A8 (pt) método in vitro de seleção de um indivíduo diagnosticado ou suspeito de ter câncer e uso de um inibidor de telomerase
AR099856A1 (es) Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
CO2019002607A2 (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contacto
ES2530743T3 (es) Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa
BR112018009463A8 (pt) ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
BR112018069316A2 (pt) métodos para detectar presença de pelo menos uma espécie de bordetella patogênica e selecionar um paciente que exibe sintomas semelhantes à coqueluche, e, kit para detectar presença de pelo menos uma espécie de bordetella patogênica.
PE20210109A1 (es) Moduladores de la expresion de irf4
BR112017005421A2 (pt) método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfr
CL2023000177A1 (es) Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa
WO2020123880A3 (en) Genomic rearrangements associated with prostate cancer and methods of using the same
EA202092797A1 (ru) Способы идентификации пациентов, для которых может быть полезным лечение ингибитором теломеразы
BR112022003935A2 (pt) Rebamipida para uso em profilaxia e tratamento de doença celíaca
AR119405A1 (es) Procedimiento de determinación del riesgo de una infección con e. coli patogénica aviar (apec) en un rebaño de aves
ECSP21042779A (es) Moduladores de la expresión de irf5